Names | |
---|---|
Preferred IUPAC name 4-{4-(4-Fluorophenyl)-2--1H-imidazol-5-yl}pyridine | |
Other names RWJ-64809; | |
Identifiers | |
CAS Number | |
3D model (JSmol) | |
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.214.849 |
EC Number |
|
IUPHAR/BPS | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
InChI
| |
SMILES
| |
Properties | |
Chemical formula | C21H16FN3OS |
Molar mass | 377.43 g/mol |
Appearance | White to off-white solid |
Solubility in DMSO | 50 mg/mL |
Hazards | |
GHS labelling: | |
Pictograms | |
Signal word | Danger |
Hazard statements | H302, H318 |
Precautionary statements | P264, P270, P280, P301+P312, P305+P351+P338, P310, P330, P501 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). N verify (what is ?) Infobox references |
SB 203580 is a specific inhibitor of p38α and p38β which suppresses downstream activation of MAPKAP kinase-2 and heat shock protein 27. At low concentrations, it does not inhibit JNK activity. SB-203580 was recently assigned the INN Adezamapimod, and is currently in phase 2 clinical trials to prevent post-operative tissue adhesion.
References
This article about an organic compound is a stub. You can help Misplaced Pages by expanding it. |